Literature DB >> 23335129

Neurocognitive variance and neurological underpinnings of the X and Y chromosomal variations.

Andrea Gropman1, Carole A Samango-Sprouse.   

Abstract

X and Y chromosomal variations including tetrasomy and pentasomy conditions are rare and occur in 1:18,000-1:100,000 male births. The most common sex chromosome aneuploidy is 47, XXY for which there is a rich literature delineating the physical and neurobehavioral phenotype. Although the more complex chromosome aneuploidies 48, XXYY, 48, XXXY, and 49, XXXXY are often compared with 47, XXY (Klinefelter syndrome) because of shared features including tall stature and hypergonadotropic hypogonadism, there is a wider spectrum of physical and cognitive abilities that have recently been delineated. The phenotypic presentation of the boys with more severe aneuploidy shares some characteristics with 47, XXY, but there are also other unique and distinctive features. Previously unappreciated intact nonverbal skills have been demonstrated in association with severe developmental dyspraxia. MRI findings of white matter hyperintensities may underlie cognitive deficits and deserve further study. This report discusses what is known about clinical variability in the XY syndromes collectively evaluated through careful multidisciplinary clinical evaluation including the clinical and neurobehavioral aspects of these conditions. Variability in clinical and cognitive functioning may reflect skewed X inactivation, mosaicism, or epigenetic factors that warrant further investigation.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23335129     DOI: 10.1002/ajmg.c.31352

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  9 in total

1.  Extensive cellular heterogeneity of X inactivation revealed by single-cell allele-specific expression in human fibroblasts.

Authors:  Marco Garieri; Georgios Stamoulis; Xavier Blanc; Emilie Falconnet; Pascale Ribaux; Christelle Borel; Federico Santoni; Stylianos E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

2.  Severe myelinopathy in 49,XXXXY syndrome.

Authors:  Mark A Buller; Cory M Pfeifer
Journal:  Neuroradiol J       Date:  2017-06-19

3.  Family experiences and attitudes about receiving the diagnosis of sex chromosome aneuploidy in a child.

Authors:  Kirsten A Riggan; Sharron Close; Megan A Allyse
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-03-17       Impact factor: 3.908

Review 4.  X chromosome regulation: diverse patterns in development, tissues and disease.

Authors:  Xinxian Deng; Joel B Berletch; Di K Nguyen; Christine M Disteche
Journal:  Nat Rev Genet       Date:  2014-04-15       Impact factor: 53.242

5.  48, XXXY/49, XXXXY mosaic: new neuroradiological features in an ultra-rare syndrome.

Authors:  Donatella Milani; Francesca Bonarrigo; Sabrina Avignone; Fabio Triulzi; Susanna Esposito
Journal:  Ital J Pediatr       Date:  2015-07-14       Impact factor: 2.638

Review 6.  Recent advances in managing and understanding Klinefelter syndrome.

Authors:  Priyanka Bearelly; Robert Oates
Journal:  F1000Res       Date:  2019-01-28

Review 7.  Update On The Clinical Perspectives And Care Of The Child With 47,XXY (Klinefelter Syndrome).

Authors:  Carole A Samango-Sprouse; Debra R Counts; Selena L Tran; Patricia C Lasutschinkow; Grace F Porter; Andrea L Gropman
Journal:  Appl Clin Genet       Date:  2019-10-23

8.  Testosterone replacement in 49,XXXXY syndrome: andrological, metabolic and neurological aspects.

Authors:  Rossella Mazzilli; Michele Delfino; Jlenia Elia; Francesco Benedetti; Laura Alesi; Luciana Chessa; Fernando Mazzilli
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-12-23

Review 9.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.